Advancements in personalized medicine and other innovations are transforming the way dosage forms are viewed.

Reshaping Dosage Forms

Novel genetic engineering technologies are transforming the design and manufacture of bispecific antibodies, which are emerging as a promising new class of biologics.

Frontrunners in Bispecific Antibodies

Topic

Articles

2026 approvals, clinical data, and licensing deals are advancing subcutaneous biologics, reducing patient burden, and reshaping biopharma drug strategy.

The Shift From Intravenous to Subcutaneous Biologics in 2026

Susan J. Schniepp is a fellow at Regulatory Compliance Associates, Inc. and a member of Pharmaceutical Technology's Editorial Advisory Board.

Videos

This episode of Pharma Fundamentals explains the difference between a quality system for biologics compared with small-molecule drugs and the Parenteral Drug Association’s revision to Technical Report No. 56.

Pharma Fundamentals: Biologics Quality System

Usha Chowdhury is Technical Services Manager, Health and Nutrition, at Univar Solutions.

Jeremy “Will” McKee is Senior Innovation Chemist at Univar Solutions.

Erin Burke, PhD, is North America technical director for Solution Centers at Univar Solutions. She leads technical teams responsible for formulation development, innovation, customer collaboration, and application testing across multiple market segments. Dr. Burke works closely with suppliers and customers to accelerate commercialization of new ingredient technologies and develop market-relevant solutions that address evolving industry and consumer needs.

The aim of this study was to develop and optimize an orally dissolving film formulation containing a blend of active ingredients in a strategic combination of natural and synthetic excipients to achieve a balance between controlled actives release and rapid onset of action.  

Orally Dissolving Films: A Modern Solution for Convenient Drug Delivery

Cynthia A. Challener is a contributing editor to Pharmaceutical Technology.

High-concentration formulations and patient centricity are challenges to the formulation of biosimilars, which already face patent protection barriers.

Overcoming Formulation Challenges for Biosimilars

Cheryl Barton is director of PharmaVision, 

New disease-modifying agents are being evaluated in the clinic that could change the course of treatment for Alzheimer’s disease patients.

European Biotechs Impacting Treatment of Alzheimer’s Disease

Patrick Lavery is an Editor for the MJH Life Sciences brands 

. Previously at MJH, he filled the same role for 

New drug delivery systems prioritize convenience and customization, using advanced technologies like nano-engineering and non-invasive routes to improve patient outcomes.

FAQ: Key Innovations in Drug Delivery and Formulation in 2025

While the deadline to make oral presentations has passed, public comment can be submitted up to a month after the workshop is held on Dec. 16.

FDA, Duke University Planning Epinephrine Access Workshop for December

Patient compliance is driving the emergence of new modalities, as Frank Romanski of Lonza Capsugel explains in the first installment of a two-part discussion.

Dosage Form Innovations: A CPHI Frankfurt Conversation with Lonza’s Frank Romanski, Part One

Feliza Mirasol is the science editor for 

Non-parenteral alternatives for biologics remain a clinical imperative and a formidable challenge.

Challenges, Innovations, and Future Outlook of Biologics Formulations

The first needle-free adrenaline treatment launches in the UK, validating non-invasive delivery with real-world data comparable to injection effectiveness.